EX-10.2 2 amlx-ex10_2.htm EX-10.2

Exhibit 10.2

Certain identified information has been excluded from this exhibit because it is both not material and

is the type that the registrant treats as private or confidential. Information that was omitted has been

noted in this document with a placeholder identified by the mark “[***]”.

AMENDMENT NO. 1, Rev 1 TO THE PRODUCTAGREEMENT

BETWEEN PATHEON INC. AND AMYLYXPHARMACEUTICALS, INC.

(“Amendment No. 1”)

This Amendment No. 1, rev 1 is effective as of January 18, 2021 (“Effective Date”) by and between Amylyx Pharmaceuticals, Inc., having a principal place of business at 43 Thorndike Street, Cambridge, MA 02141 (“Client”) and Patheon Inc., having a principal place of businessat 111 Consumers Drive, Whitby, Ontario L1N 5Z5 (“Patheon”).

WHEREAS Client and Patheon entered into a Master Manufacturing Services Agreement effective November 12, 2019 (the “Agreement”);

AND WHEREAS pursuant to the Agreement, Patheon and Client entered into a Product Agreement for AMX0035 effective November 12, 2019 (the “Product Agreement”);

AND WHEREAS Client and Patheon mutually desire to amend Schedule A to the Product Agreement with respect to pricing, process train and batch size (“Schedule A”);

NOW THEREFORE in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:

1.
Schedule A is herebydeleted in its entirety and replaced with a new Schedule A attached hereto as Exhibit A.
2.
Except as expressly provided in this Amendment No. 1, rev 1 all other terms, conditions and provisions of the Agreement and the ProductAgreement shall apply and remain in full force and effect. To the extent there are any inconsistencies or ambiguities between the terms of this Amendment No. 1, rev 1 and the Agreement or the Product Agreement, the terms of this Amendment No. 1, rev 1 shall supersede and prevail.
3.
This AmendmentNo. 1, rev 1 may be executedin two counterparts each of which shall be deemed an original but both of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to sign this Amendment No. 1 upon the date first set forth above.

AMYLYX PHARMACEUTICALS, INC. PATHEON INC.

By:/s/ Joshua Cohen By:/s/ Bobbi Ellis

Name: Joshua Cohen

Title: CEO

Name: Bobbi Ellis

Title: Senior Director & General Manager

EXHIBIT A

“SCHEDULE A COMMERCIAL SUPPLY PRICING PROPOSAL

[***]